发明名称 |
Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and process for preparing them |
摘要 |
Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution. A pre-made mixture of part of the cross-linked carboxymethyl-cellulose and the rest of the ingredients of the composition is impregnated with the solution and is dried and grinded, and is added to the rest of the cross-linked carboxymethyl-cellulose and the flavoring additives, being then mixed and compressed. |
申请公布号 |
US9308212(B2) |
申请公布日期 |
2016.04.12 |
申请号 |
US201314102934 |
申请日期 |
2013.12.11 |
申请人 |
LABORATORIOS BAGO S.A. |
发明人 |
Los Mario Atilio |
分类号 |
A61K31/5517;A61K9/00;A61K9/20 |
主分类号 |
A61K31/5517 |
代理机构 |
Dinsmore & Shohl LLP |
代理人 |
Dinsmore & Shohl LLP |
主权项 |
1. A pharmaceutical composition in the form of sublingual tablets characterised by:
comprising combination of alprazolam and a binder having mucoadhesive properties; wherein the ratio of alprazolam to the binder is in the range between 0.3:1 and 3:1; and, wherein said composition has a disintegration time lower than 30 seconds, in vitro when measured in a standard USP apparatus in medium water without discs according to the United States Pharmacopoeia; and wherein the degree of crystallinity of the alprazolam is less than 10%. |
地址 |
Buenos Aires AR |